急性支氣管炎に対するアジトロマイシン:ランダム化,ダブルブラインド,制御試験
Arthur T Evans1, Shahid Husain, Lakshmi Durairaj
1Collaborative Research Unit, Department of Medicine, Cook County Hospital and Rush Medical College, Chicago, IL 60612, USA. aevans@cchil.org
Lancet (London, England)
|May 22, 2002
まとめ
アジトロマイシンは,急性支障管炎の治療にビタミンCよりも利点がありません. この一般的な呼吸器疾患の最適な管理を決定するために,さらなる研究が必要である.
科学分野:
- 呼吸器医学とは
- クリニック・トライアル 臨床試験
- 薬理学 薬理学とは
背景:
- 急性支氣管炎は,アジトロマイシンの有効性を裏付ける証拠が不足しているにもかかわらず,アジトロマイシンで頻繁に治療されています.
- 急性支氣管炎に対するアジトロマイシンの有効性は,厳格な臨床試験ではほとんど調査されていません.
研究 の 目的:
- 急性支末炎の治療におけるアジトロマイシンの有効性をビタミンCと比較して評価する.
- 急性支氣管炎患者の健康関連の生活の質への影響を評価する.
主な方法:
- 急性肺炎と診断された成人を対象に,ランダム化,ダブルブラインド,制御試験が行われました.
- 参加者はアジトロマイシンまたはビタミンCを5日間,デクストロメソルファンとアルブテロールと共に投与された.
- 測定された主なアウトカムは,7日後の健康関連の生活の質の改善であり,治療の意図によって分析されました.
主要な成果:
- アジトロマイシンは,ビタミンCと比較して7日後に健康関連の生活の質の有意な改善を示さなかった (差異0.03,p=0.8).
- 7日目までに通常の活動への復帰は,グループ間 (89%),統計的に有意な差異はありませんでした.
- 副作用の頻度は比較可能で,ビタミンC群では,副作用が認められたため中止がわずかに多かった.
結論:
- アジトロマイシンは,急性支障管炎の治療において,低用量ビタミンCに優れているわけではありません.
- 急性支氣管炎の最も効果的な治療戦略を確立するために,さらなる研究が必要である.
関連する概念動画
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:26Tonsillitis II: Management
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: